TY - JOUR
T1 - High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas
AU - Yusenko, Maria V
AU - Kuiper, Roland P
AU - Boethe, Tamas
AU - Ljungberg, Börje
AU - van Kessel, Ad Geurts
AU - Kovacs, Gyula
N1 - Funding Information:
This study was supported by a grant from the Wilhelm Sander Stiftung (to GK) and a grant from the Dutch Cancer Society (to AGvK). The authors thank Ms. E.J. Kamping for technical assistance and J.B. Cazier for GWA consults. We also thank the Genomics Core Facility at the EMBL for their technical assistance in the GeneChip expression analysis.
PY - 2009/5/18
Y1 - 2009/5/18
N2 - BACKGROUND: The diagnosis of benign renal oncocytomas (RO) and chromophobe renal cell carcinomas (RCC) based on their morphology remains uncertain in several cases.METHODS: We have applied Affymetrix GeneChip Mapping 250 K NspI high-density oligoarrays to identify small genomic alterations, which may occur beyond the specific losses of entire chromosomes, and also Affymetrix GeneChip HG-U133 Plus2.0 oligoarrays for gene expression profiling.RESULTS: By analysing of DNA extracted from 30 chRCCs and 42 ROs, we have confirmed the high specificity of monosomies of chromosomes 1, 2, 6, 10, 13, 17 and 21 in 70-93% of the chRCCs, while ROs displayed loss of chromosome 1 and 14 in 24% and 5% of the cases, respectively. We demonstrated that chromosomal gene expression biases might correlate with chromosomal abnormalities found in chromophobe RCCs and ROs. The vast majority genes downregulated in chromophobe RCC were mapped to chromosomes 2, 6, 10, 13 and 17. However, most of the genes overexpressed in chromophobe RCCs were located to chromosomes without any copy number changes indicating a transcriptional regulation as a main event.CONCLUSION: The SNP-array analysis failed to detect recurrent small deletions, which may mark loci of genes involved in the tumor development. However, we have identified loss of chromosome 2, 10, 13, 17 and 21 as discriminating alteration between chromophobe RCCs and ROs. Therefore, detection of these chromosomal changes can be used for the accurate diagnosis in routine histology.
AB - BACKGROUND: The diagnosis of benign renal oncocytomas (RO) and chromophobe renal cell carcinomas (RCC) based on their morphology remains uncertain in several cases.METHODS: We have applied Affymetrix GeneChip Mapping 250 K NspI high-density oligoarrays to identify small genomic alterations, which may occur beyond the specific losses of entire chromosomes, and also Affymetrix GeneChip HG-U133 Plus2.0 oligoarrays for gene expression profiling.RESULTS: By analysing of DNA extracted from 30 chRCCs and 42 ROs, we have confirmed the high specificity of monosomies of chromosomes 1, 2, 6, 10, 13, 17 and 21 in 70-93% of the chRCCs, while ROs displayed loss of chromosome 1 and 14 in 24% and 5% of the cases, respectively. We demonstrated that chromosomal gene expression biases might correlate with chromosomal abnormalities found in chromophobe RCCs and ROs. The vast majority genes downregulated in chromophobe RCC were mapped to chromosomes 2, 6, 10, 13 and 17. However, most of the genes overexpressed in chromophobe RCCs were located to chromosomes without any copy number changes indicating a transcriptional regulation as a main event.CONCLUSION: The SNP-array analysis failed to detect recurrent small deletions, which may mark loci of genes involved in the tumor development. However, we have identified loss of chromosome 2, 10, 13, 17 and 21 as discriminating alteration between chromophobe RCCs and ROs. Therefore, detection of these chromosomal changes can be used for the accurate diagnosis in routine histology.
KW - Adenoma, Oxyphilic/genetics
KW - Carcinoma, Renal Cell/genetics
KW - Chromosomes, Human/genetics
KW - Gene Dosage
KW - Gene Expression Profiling
KW - Humans
KW - Kidney Neoplasms/genetics
KW - Oligonucleotide Array Sequence Analysis
KW - Tumor Cells, Cultured
UR - http://www.scopus.com/inward/record.url?scp=66749104378&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-9-152
DO - 10.1186/1471-2407-9-152
M3 - Article
C2 - 19445733
SN - 1471-2407
VL - 9
SP - 152
JO - BMC cancer
JF - BMC cancer
M1 - 152
ER -